KRAS and lung adenocarcinoma: However, co-mutations may alter such efficacy, such as KRAS-mutant patients with STK11 or KEAP1, as co-mutations have a poorer prognosis for immunotherapy than KRAS wild-type lung adenocarcinoma patients [54].